주사용 약물전달 시장 : 디바이스, 제제, 제제 포장, 용도, 투여 부위, 사용 패턴, 사용성, 최종 용도별 - 세계 예측(2024-2032년)

Injectable Drug Delivery Market size is poised to record 9.4% CAGR over 2024-2032, due to rising partnerships between pharmaceutical companies and technology firms to develop innovative drug delivery systems. Collaborative efforts are driving significant advancements in drug delivery technologies for ultimately improving patient care and addressing complex medical challenges. The surging R&D investments to explore new delivery mechanisms and enhance existing technologies will also define the industry growth. For example, in January 2024, DelSiTech secured EUR 10 million in funding for advancing its silica-based drug delivery technology platform.

The injectable drug delivery industry is segmented into devices, formulation, formulation packing, application, site of administration, usage pattern, usability, end-use, and region.

In terms of formulation packing, the industry value from the cartridges segment may record robust CAGR from 2024 to 2032. Injectable drug delivery cartridges simplify the drug administration process for patients and healthcare providers as they can be pre-filled for use, thus, reducing the steps required for preparation and minimizing the risk of dosing errors. Innovations in cartridge designs and materials for enhancing functionality in various applications will also add to the product demand.

By site of administration, the injectable drug delivery industry from the skin segment will expand through 2032 due to the ongoing research for improving delivery mechanisms, enhancing patient comfort, and expanding the range of treatable conditions. Injectable drug delivery is used for managing potential adverse skin reactions, such as irritation, inflammation, or allergic responses. Rapid innovations in materials science, biotechnology, and device engineering will also boost the segment growth.

Regionally, the Asia Pacific injectable drug delivery market size may witness significant CAGR through 2032, mainly led by the prevalence of chronic diseases, such as diabetes and cancer along with the strong need to offer precise dosage control and improved patient outcomes. The evolving regulatory frameworks are encouraging innovations and ensuring that the safety and efficacy standards are met.

The escalating healthcare infrastructure and rising healthcare expenditure in China, India, and Southeast Asia will also favor the regional industry growth.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Escalation in demand for self-injection devices
    • 3.2.1.2 Increase in the number of chronic diseases
    • 3.2.1.3 Innovative technological progress
    • 3.2.1.4 Development of the biologics market
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Needlestick injuries and infections
    • 3.2.2.2 Preference over other drug delivery systems
    • 3.2.2.3 Sterility of injectables
• 3.3 Growth potential analysis
• 3.4 Reimbursement scenario
• 3.5 Regulatory landscape
• 3.6 Technological landscape
  • 3.6.1 Core technologies
  • 3.6.2 Adjacent technologies
• 3.7 Pricing analysis, 2023
  • 3.7.1 By region
  • 3.7.2 By key player
• 3.8 Future market trends
• 3.9 Porter's analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Devices, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Conventional injection devices
  • 5.2.1 Fillable syringes
  • 5.2.2 Prefilled syringes
• 5.3 Self-injection devices
• 5.4 Needle-free injectors
  • 5.4.1 Jet-based needle-free injectors
  • 5.4.2 Spring-based needle-free injectors
  • 5.4.3 Laser-powered needle-free injectors
  • 5.4.4 Vibration-based needle-free injectors
• 5.5 Autoinjectors
  • 5.5.1 Automated autoinjectors
  • 5.5.2 Manual autoinjectors
• 5.6 Pen injectors
  • 5.6.1 Single-chambered pen injectors
  • 5.6.2 Dual-chambered pen injectors
• 5.7 Wearable injectors
• 5.8 Other devices

Chapter 6 Market Estimates and Forecast, By Formulation, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Conventional drug delivery formulations
  • 6.2.1 Solutions
  • 6.2.2 Reconstituted/lyophilized formulations
  • 6.2.3 Suspensions
  • 6.2.4 Emulsions
• 6.3 Novel drug delivery formulations
  • 6.3.1 Colloidal dispersions
  • 6.3.2 Niosomes
  • 6.3.3 Liposomes
  • 6.3.4 Polymeric/mixed micelles
  • 6.3.5 Nanoparticles
  • 6.3.6 Solid-lipid nanoparticles
  • 6.3.7 Nanosuspensions
  • 6.3.8 Nanoemulsions
• 6.4 Microparticles
  • 6.4.1 Microspheres
  • 6.4.2 Microcapsules
• 6.5 Long-acting injection formulations

Chapter 7 Market Estimates and Forecast, By Formulation Packing, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Ampoules
• 7.3 Vials
• 7.4 Cartridges
• 7.5 Bottles

Chapter 8 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Autoimmune diseases
  • 8.2.1 Rheumatoid arthritis
  • 8.2.2 Multiple sclerosis
  • 8.2.3 Crohn's disease
  • 8.2.4 Psoriasis
  • 8.2.5 Other autoimmune diseases
• 8.3 Hormonal disorders
  • 8.3.1 Diabetes
  • 8.3.2 Anemia
  • 8.3.3 Reproductive health disease
  • 8.3.4 Antithrombotic/thrombolytic therapy
  • 8.3.5 Osteoporosis
  • 8.3.6 Growth hormone deficiency
• 8.4 Orphan diseases
• 8.5 Cancer
• 8.6 Infectious diseases
• 8.7 Other applications

Chapter 9 Market Estimates and Forecast, By Site of Administration, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 Skin
• 9.3 Circulatory/musculoskeletal system
• 9.4 Organs
• 9.5 Central nervous system

Chapter 10 Market Estimates and Forecast, By Usage Pattern, 2021 - 2032 ($ Mn)

• 10.1 Key trends
• 10.2 Curative care
• 10.3 Immunization
• 10.4 Other usage patterns

Chapter 11 Market Estimates and Forecast, By Usability, 2021 - 2032 ($ Mn)

• 11.1 Key trends
• 11.2 Disposable
• 11.3 Reusable

Chapter 12 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

• 12.1 Key trends
• 12.2 Hospitals and clinics
• 12.3 Ambulatory surgical centers
• 12.4 Home care settings
• 12.5 Other end-users

Chapter 13 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 13.1 Key trends
• 13.2 North America
  • 13.2.1 U.S.
  • 13.2.2 Canada
• 13.3 Europe
  • 13.3.1 Germany
  • 13.3.2 UK
  • 13.3.3 France
  • 13.3.4 Spain
  • 13.3.5 Italy
  • 13.3.6 Netherlands
  • 13.3.7 Rest of Europe
• 13.4 Asia Pacific
  • 13.4.1 China
  • 13.4.2 Japan
  • 13.4.3 India
  • 13.4.4 Australia
  • 13.4.5 South Korea
  • 13.4.6 Rest of Asia Pacific
• 13.5 Latin America
  • 13.5.1 Brazil
  • 13.5.2 Mexico
  • 13.5.3 Argentina
  • 13.5.4 Rest of Latin America
• 13.6 Middle East and Africa
  • 13.6.1 South Africa
  • 13.6.2 Saudi Arabia
  • 13.6.3 UAE
  • 13.6.4 Rest of Middle East and Africa

Chapter 14 Company Profiles

• 14.1 A. Menarini Diagnostics s.r.l
• 14.2 Abbott Laboratories
• 14.3 ARKRAY, Inc.
• 14.4 Becton, Dickinson and Company
• 14.5 Bio-Rad Laboratories, Inc.
• 14.6 Ceragem Medisys Inc.
• 14.7 Danaher Corporation
• 14.8 EKF Diagnostics
• 14.9 Eli Lilly and Company
• 14.10 F. Hoffmann-La Roche Ltd.
• 14.11 Pfizer Inc.
• 14.12 PTS Diagnostics
• 14.13 SAKAE HOLDINGS LTD.
• 14.14 Sanofi
• 14.15 SEKISUI CHEMICAL CO., LTD.
• 14.16 Siemens Healthineers AG
• 14.17 Trinity Biotech plc